Home · Research · Longevity & bioregulators

Crystagen research

What published studies found for Crystagen: 1 paper, 0 in humans, with sample sizes and key results.

Little or no evidence

Why: Essentially nothing: a single Russian review mentions B-cell effects with no data; no animal or human studies.

Crystagen (reported as the peptide Glu-Asp-Pro) has almost no published literature. One Russian review of spleen ageing reports that it activates B cells without renewing spleen cells; nothing else directly tests it. There are no human studies.

? 1 inconclusive

No human studies and no human safety data; the compound is essentially unstudied in the published literature.

US compounding: Not compoundable. Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it. Status for every peptide.

Browse and filter these papers Crystagen prices and vendors

Reviews

? InconclusivereviewAdv Gerontol · 2014

[Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process].

No new dataReview

A review of spleen ageing reports that Crystagen activates B cells but, unlike the comparator peptides Vilon and R-1, does not drive cell renewal in the ageing spleen; no quantitative or clinical data are given.

Studied: Spleen immune cells during ageing (review of peptide effects including Vilon, Timogen, Crystagen, R-1)
Main outcome: Immunoprotective effects of short peptides in the spleen
Authors' conclusion: Crystagen activates B-cells of the immune system but does not cause cell renewal in the spleen as it ages, unlike some of the other peptides reviewed.
Limitations: Review of the authors' group's work; no numbers in abstract.

PubMed 28976144

Verdicts are judged on each paper's own main outcome; grades run from A (strong human evidence) to D (little or none). Details are read from the abstracts, and figures are reproduced only from openly licensed full texts. Not medical advice.